Zoetis Inc. (NYSE:ZTS) Shares Acquired by XTX Topco Ltd

XTX Topco Ltd increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 129.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,219 shares of the company’s stock after acquiring an additional 13,103 shares during the quarter. Zoetis makes up approximately 0.3% of XTX Topco Ltd’s holdings, making the stock its 18th biggest holding. XTX Topco Ltd’s holdings in Zoetis were worth $4,025,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. Webster Bank N. A. lifted its stake in Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares during the last quarter. Neo Ivy Capital Management bought a new stake in Zoetis in the 4th quarter valued at about $40,000. LRI Investments LLC acquired a new position in Zoetis during the 1st quarter valued at about $43,000. Ables Iannone Moore & Associates Inc. bought a new position in Zoetis in the 4th quarter worth about $51,000. Finally, Hazlett Burt & Watson Inc. increased its stake in shares of Zoetis by 60.7% in the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after purchasing an additional 102 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE:ZTS opened at $196.48 on Thursday. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The firm has a market cap of $89.65 billion, a P/E ratio of 37.86, a PEG ratio of 2.98 and a beta of 0.88. The business’s 50-day moving average price is $184.11 and its 200 day moving average price is $174.31.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter in the previous year, the company posted $1.41 EPS. The business’s revenue was up 8.3% compared to the same quarter last year. As a group, sell-side analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ZTS shares. Piper Sandler increased their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus increased their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday. BTIG Research lifted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Zoetis has an average rating of “Buy” and an average target price of $218.22.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.